Plain-English translation of NCT07219771 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing PTP-001 (MOTYS™), a treatment made from human placental tissue that is injected directly into the knee joint. Researchers want to know if this single injection can safely reduce pain and improve function in people with mild to moderate knee osteoarthritis. Half of the participants will receive the active treatment, and half will receive a placebo (salt water) injection, so doctors can fairly compare how well it works.
Knee arthritis causes chronic pain that doesn't always respond well to oral pain relievers or anti-inflammatory drugs. This trial is testing whether this medication—delivered directly into the knee—might offer a new, longer-lasting option for people who haven't had success with standard treatments.
You likely qualify if…
You likely don't qualify if…
You'll have an initial screening visit (within 28 days before treatment) where doctors confirm you have knee arthritis and measure your pain level. On Day 1, you'll receive a single injection into your knee—either the active treatment or a placebo. Then you'll return for follow-up visits over the next 12 months to track your pain, function, and any side effects. During the study, you can only use acetaminophen (Tylenol) as a rescue pain medication, and you'll need to avoid other pain relievers.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States